ISLEND-2 – GS-US-563-5926
A Phase 3 Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1. Who are Virologically Suppressed on Standard of Care
EU CT Number: 2024-514047-28
ARTISTRY 1 GS-US-621-6289
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens.
EU CT Number: 2022-500929-33-00
VOLITION 219700
A Phase IIIb, multi-center, non-randomized, parallel-group, open-label, hybrid type I study evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral dolutegravir/lamivudine once-daily as a first-line regimen followed by participant-determined optional switch to long-acting intramuscular cabotegravir plus rilpivirine every two months for the maintenance of virologic suppression in antiretroviral therapy naive adults living with HIV-1.
EU CT Number: 2023-503893-19-00
Illuminate MK-8591A-020:
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants;
EudraCT No: 2019-000590-2323
Illuminate-Shift MK-8591A-018-00:
A Phase III, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaliuate a Switch to Doravirine/Islatravir(DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF);
EudraCT No.2019-000587-23
ISR-003: A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult patients on suppressive ART
EudraCT No. 2017-004160-35
CARISEL 213199: A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically suppressed adults in select European healthcare settings; EudraCT No: 2020-000424-19
SALSA 208090: Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed Treatment; EudraCT No. 2018-000177-72
Atlas-2M 207966: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority,Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting,Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed; EudraCT No. 2017-002946-62
Illuminate HTE MK-8591A-019: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL; EudraCT No: 2019-000588-26
Domino 208379: Phase IIb, randomized, partially blind, active controlled, dose-range
finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcriptase inhibitors, in HIV-1 infected antiretroviral treatment-naive adults; EudraCT No: 2019-004435-23
Latte-2 200056: A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regimen of GSK1265744 plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects; EUDRACT No.: 2013-000783-29
Tango 204862: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed; EudraCT No: 2015-004401-17
Atlas 201585: A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed; EUDRACT No: 2016-001647-39
Flair 201584: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants; EUDRACT No: 2016-001646-25
GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/F/TAF (GS-9883/Emtricitabine/Tenofovir Alafenamide) Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults; EUDRACT No: 2015-004024-54
GS-US-380-1490: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV‑1 Infected, Antiretroviral Treatment-Naive Adults; EUDRACT No: 2015-003988-10
GS-US-380-1844: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV‑1 Infected Subjects who are Virologically Suppressed; EUDRACT No: 2015-004025-14
GS-US-380-1878: A Phase 3, Randomized, Open‑Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults; EUDRACT Number: 2015-004011-20
DRIVE-SHIFT MK 1439-024: Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors; EUDRACT Number: 2014-005550-18
AI468038: A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults; EUDRACT Number: 2013-005487-26
AI438047: A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1; EUDRACT Number: 2014-002111-41
GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF); EudraCT Number: 2014-004545-27
GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects; EudraCT Number:2014-004779-21
DRIVE FORWARD MK 1439-018: A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects; EudraCT NUMBER: 2014-001127-69
MK-0518 – 292-00: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects; EudraCT NUMBER: 2013-001939-47
GS-US-104-0423: Study Title: A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects; EUDRACT-NR.: 2011-004420-35
GS-US-292-0109: “A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects“; EUDRACT-NR.: 2012-005114-20
GS-US-236- 0121 – STRATEGY: A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients; EUDRACT-NR.: 2011-004963-56
Pfizer A4001095: A multicenter, randomized, double-blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine /tenofovir + Darunavir/Ritonavir for Treatment of Antiretroviral- naïve HIV Infected Patients with CCR5-Tropic HIV-1; EudraCT-Nr.: 2010-021785-30
BI 1220.19: Safety and Efficacy of 240mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV co- infected patients . A multinational, randomized, parallel group , open label trial; EudraCT-Nr.: 2007-003654-29
GS-US-264-0110: A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults; EudraCT Number: 2010-024007-27
GSK ING 114467 – SINGLE: A Phase 3, randomized, double-blind study of the safety and efficacy of GSK 1349572 plus abacavir/lamivudine fixed-dose combination therapy administered Once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects; EudraCT-Nummer: 2010.020983-39
GSK ING 113086 – SPRING-2: A Phase 3, randomized, double-blind study of the safety and efficacy of GSK 1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects; EudraCT-Nummer:2009-017950-11
MUC NewEra 3.1; HIV and Eradication: A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected CD4+ T cells. EudraCT-Nummer: 2008-002070-35; Ethik-Kommission Nr. 08101
GSK – Phase 1 – Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462; EudraCT Number: 2008-005009-20
A4001078: Pilot study of novel combination of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir for the treatment of treatment naive HIV – infected patients with R5 HIV -1; EudraCT Number: 2008-007038-24
GS-US-236-0103 Quad: A Phase 3, Randomized;Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-Infected;Antiretroviral Treatment-Naïve Adults; EudraCT Number:2009-016758-42
Verxve BI 1100.1486: A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada® in antiretroviral therapy naïve HIV-1 infected patients; EudraCT Number: 2007-003654-29
POEM A4001067: An international, multi-center, prospective epidemiologic cohort study of the safety of maraviroc used with optimized background therapy in treatment experienced HIV-1 infected patients; EudraCT Number:2007-006148-24
GS-US-183-0145: A multicenter, randomized, double-blind,double-dummy, phase 3 study of the safety and efficacy of ritonavir boosted Elvitegravir(EVG/r) versus Raltegravir(RAL) each administered with a background regime in HIV-Infected, antiretroviral treatment experienced adults
MK 0518-071: A phase III multicenter, double blind, randomized, active comparator-controlled clinical trial to study the safety and efficacy of once daily Raltegravir versus twice daily Raltegravir, each in combination with Truvada in NAIVE PATIENTS
TMC 114-C211: A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects; EudraCT Number: 2005-002486-36
Victor-4: Vicriviroc in Combination Treatment with an optimized ART Regimen in HIV-infected Treatment-Experienced Subjects; EudraCT Number: 2006-006417-32
MK 0518-018: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of Mk-0518 in Combination With an Optimized Background Therapy (OBT), Vesus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed oral Antiretroviral Therapies; EudraCT Number: 2005-005127-34
Assert CAN 109586: Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naïve, HIV-1 Infected Adult Subjects; EudraCT Number:2007-000454-31
MK 0518-032: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Kaletra in HIV-Infected Patients Switched from a Stable Kaletra -Based Regime- Study A; EudraCT Number: 2007-000783-25
MK 0518-023: Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment.
BI 1100.1452: A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxity or Severe Cutaneous Toxicity within the First 8 weeks of Nevirapine Therapy; EudraCT Number: 2005-004321-26
Predict HSR-CAN 106030: A phase IV, randomised,multicentre, double-blind,study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity.
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir („TMC114/r“) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
TMC 125-C216: A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety to TMC125 as a part of an ART including TMC114/RTV and an investigator- selected OBR in HIV-1 infected subjects with limited to no treatment options; EudraCT Number: 2005-003160-32
A4001050: A multicenter, open label, expanded access trial of Maraviroc.
TMC 125-C217: An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216).” (TMC125-C217); EudraCT Number: 2005-003160-32
TMC 125-C214: Early Access of TMC125 in combination with other antiretrovirals in treatment experienced HIV-1 infected subjects with limited treatment options; EudraCT number: 2006-002499-16
HPR20001: A Phase IIB, Randomized, Multicenter, parallel Group Study to Evaluate the Short-term Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-Label Current PI therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen.Ethik-Kommissio Nr. 7/05148
TMC114-C208: An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201;TMC114-C207 or in sponser selected Phase I trials
Ethik-Kommission Nr. 7/04322
A phase II randomized, controlled, partially blinded, 48-week trial to investigate dose-response of TMC114/RTV in 3-class-experienced, multi PI-experienced HIV-1 infected subjects.
Ethik-Kommission Nr. 03193
SILCAAT: Multizentrische, randomisierte Phase-III-Studie zur Untersuchung der biologischen und klinischen Wirksamkeit von subkutan verabreichtem, rekombinanten humanen Interleukin-2 an HIV-infizierten Patienten mit niedrigen CD4+- Werten unter aktiver antiretroviraler Therapie. Ethik-Kommission Nr. 99117
TMC114-C215: Eine offene Studie über 48 Wochen mit TMC114/RTV bei HIV-1-infizierten Patienten, bei denen die Studien-Behandlung in der Kontrollgruppe in einer ausgewählten Studie mit TMC114 versagt hat. Ethik-Kommission Nr. 04017
FRAN-03-001: A pilot, open label, randomized, comparative study of the antiviral efficacy of lopinavir/ritonavir single-drug regime versus lopinavir/ritonavir in combination with lamivudine/zidovudine in antiretroviral naïve patients Ethik-Kommission Nr. 7/04241
HIV-NEF-004: Vergleichende Studie zur Wirksamkeit und Sicherheit eines neuen Impfstoffes MVA-BN nef in zwei zu vergleichenden Dosierungen bei HIV pos. Patienten mit CD4> 250/µl unter der Prüfleitung von Prof. Dr. med. Thomas Harrer, Universitätsklinikum Erlangen; Ethik-Kommission Nr. bayUni 0432
TMC114-C151: „The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects “,unter der Prüfleitung von Herrn Priv.-Doz. Dr. Keikawus Arastéh, Epimed GmbH, Berlin; EudraCT-Nr. 2004-004990-27
TPV-Studie 1182.68: An open label safety study of Tipranavir co-administered with low-dose Ritonavir (TPV/r) in patients with advanced HIV-1 infection and limited treatment options; Ethik-Kommission Nr. 7/04140
TPV-Studie 1182.17: A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects; Ethik-Kommission Nr. 7/03090
TPV-Studie: Studiennummer 1182.48
Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-expirienced patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir); Ethik-Kommission Nr. 7/03007
APV30005: An open-label phase III study to assess the long term safety profile of GW433908 containing regimens in HIV-1 infected subjects; Ethik-Kommission Nr. 02052
APV40003: Sicherheit und Wirksamkeit von GW433908 im Rahmen der antiretroviralen Kombinationstherapie bei HIV-infizierten Patienten
Ethik-Kommission Nr. 02140
ABT – 378/r (ABT – 378/ritonavir) Early Access Program, Protocol Number M99-046; Programm für die vorzeitige Anwendung von ABT 378/r Ethik-Kommission Nr. 7 / 874
Serostim – Recombinant Human Growth Hormone, mammalian-cell derived, (r-hGH (m), somatropin) – A randomized, parallel group, double-blind, placebo-controlled, dose-ranging, multicenter study of recombinant human growth hormone in the treatment of HIV-associated catabolism / wasting; Ethik-Kommission Nr. 99146
AI424-009: Untersuchung zur antiretroviralen Wirksamkeit von zwei verschiedenen Dosierungen eines neuen Hemmstoffes der HIV-1 Protease, BMS-232632, in Kombination mit Saquinavir und zwei neuen NRT‘s bei vorbehandelten Patienten mit Therapieversagen unter einer Dreifachkombination; Ethik-Kommission Nr. 99227
PRO30013: Offene Prüfung einer Amprenavir- Behandlung bei erwachsenen Patienten mit HIV-Infektion, bei denen eine Standardtherapie mit Protease-Inhibitoren versagt hat oder nicht vertragen wurde; Ethik-Kommission Nr. 7 / 677
Studie AZL30002 (Trizal – Studie); Ethik-Kommission Nr. 7 / 850
INITIO-Trial: Eine offene, randomisierte Studie zur Evaluierung von verschiedenen therapeutischen Strategien in der Kombinationstherapie zur Behandlung der HIV-1-Infektion; Ethik-Kommission Nr. 99024
Studie GS-99-903: A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral Naïve, HIV-1 Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination with Lamivudine and Efavirenz Versus Stavudine, Lamivudine and Efavirenz; Ethik-Kommission Nr. 00070
I424-900: Atazanavir (BMS-232632) for HIV Infectet individuals: An Early Access Programm; Ethik-Kommission Nr. 7/02189
A Phase III, Randomized;Open Label,Parallel, Multiccenter Study to Evaluate Treatment with Fixed-Dose Combination of Abacavir/Lamivudine (600mg/300mg) Once daily versus Abacavir (300mg) Twice-Daily and Lamivudine (300mg) Once-Daily in Combination with Tenofovir Once-Daily and a new PI or NNRTI for 48 weeks in ART-Experienced HIV-1 Infected Patients; Ethik-Kommission Nr. 02073
R278474-C202: A phase II, proof of principle (POP), randomized, open label trial in HIV-1 infected subjects with NNRTI experience and/or genotypic evidence of NNRTI resistance, who will receive R278474 once daily for 7 days in substitution for the NNRTI or PI in failing ART; Ethik-Kommission Nr. bayUni0429
T20-305/NV16391: A phase III open-label safety study of T-20/Ro 29-9800, (HIV-1 fusion inhibitor) in combination with oral antiretroviral, in patients who are unable to construct a viable regime; Ethik-Kommission Nr. 7/02009
